Conmed (CNMD) Tops Q4 EPS by 1c

Conmed (NYSE: CNMD) reported Q4 EPS of $1.07, $0.01 better than the analyst estimate of $1.06. Revenue for the quarter came in at $274 million versus the consensus estimate of $278.76 million.

GUIDANCE:

Conmed sees FY2022 EPS of $3.60-$3.85, versus the consensus of $3.74. Conmed sees FY2022 revenue of $1.075-1.125 billion, versus the consensus of $1.11 billion.

For earnings history and earnings-related data on Conmed (CNMD) click here.

You May Also Be Interested In

• Cooper Cos. (COO) Tops Q3 EPS by 3c, Offers Guidance
• ABM Industries (ABM) Reports In-Line Q3 EPS; raises guidance
• Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent